PRA Health Sciences, Inc. (NASDAQ:PRAH) – Equities research analysts at Jefferies Group increased their FY2017 earnings estimates for PRA Health Sciences in a research report issued on Tuesday. Jefferies Group analyst D. Windley now anticipates that the firm will post earnings of $3.03 per share for the year, up from their prior forecast of $3.00. Jefferies Group currently has a “Buy” rating and a $66.00 target price on the stock.
PRA Health Sciences (NASDAQ:PRAH) last announced its quarterly earnings data on Wednesday, November 2nd. The company reported $0.64 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.64. The company had revenue of $399.80 million for the quarter, compared to analysts’ expectations of $394.87 million. PRA Health Sciences had a return on equity of 21.25% and a net margin of 4.86%. PRA Health Sciences’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same period last year, the firm posted $0.52 EPS.
PRAH has been the subject of several other research reports. TheStreet raised PRA Health Sciences from a “hold” rating to a “buy” rating in a report on Monday, November 14th. Zacks Investment Research raised PRA Health Sciences from a “hold” rating to a “strong-buy” rating and set a $65.00 price target for the company in a report on Wednesday, October 5th. Credit Suisse Group reissued a “hold” rating and set a $50.00 price target on shares of PRA Health Sciences in a report on Thursday, November 3rd. Finally, KeyCorp reissued a “buy” rating on shares of PRA Health Sciences in a report on Friday, November 4th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $57.14.
PRA Health Sciences (NASDAQ:PRAH) opened at 55.42 on Thursday. PRA Health Sciences has a one year low of $35.60 and a one year high of $60.96. The company’s 50 day moving average price is $55.47 and its 200-day moving average price is $52.80. The stock has a market capitalization of $3.40 billion, a PE ratio of 43.03 and a beta of 0.53.
Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. raised its position in shares of PRA Health Sciences by 26.0% in the second quarter. BlackRock Inc. now owns 2,399 shares of the company’s stock worth $100,000 after buying an additional 495 shares during the last quarter. US Bancorp DE purchased a new position in shares of PRA Health Sciences during the third quarter worth approximately $106,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of PRA Health Sciences by 7.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,025 shares of the company’s stock worth $114,000 after buying an additional 133 shares during the last quarter. BNP Paribas Arbitrage SA raised its position in shares of PRA Health Sciences by 120.5% in the third quarter. BNP Paribas Arbitrage SA now owns 2,093 shares of the company’s stock worth $118,000 after buying an additional 1,144 shares during the last quarter. Finally, Fuller & Thaler Asset Management Inc. purchased a new position in shares of PRA Health Sciences during the third quarter worth approximately $124,000. 99.82% of the stock is owned by hedge funds and other institutional investors.
PRA Health Sciences Company Profile
PRA Health Sciences, Inc is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.